GSK PLC GSK shares inched down 0.55% to £13.62 Wednesday, on what proved to be an all-around great trading session for the stock market, with the FTSE 100 Index UKX rising 0.06% to 8,030.33. Supported ...
GSK Plc agreed on a partnership deal worth as much as $650 million with US biotech Vesalius Therapeutics to help advance drug ...
13d
GSK PLC (GSK) reports robust year-to-date sales growth, driven by Specialty Medicines, while navigating vaccine sales ...
GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...
Under deal terms, GSK will give Vesalius Therapeutics $80 million in upfront and equity payments to identify treatments for ...
GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...
GSK added Ojjaara to its portfolio through the acquisition of Sierra in 2022. Credit: Magda Wygralak via Shutterstock. Health ...
GSK plc (LON:GSK – Get Free Report) insider Jonathan Symonds bought 7,150 shares of the stock in a transaction dated ...
Despite the rise of a vaccine skeptic in the campaign of US presidential election winner Donald Trump, GSK CEO Emma Walmsley ...
Despite significant medical advancements in the oncology space, 30% of patients in the GSK/Harris Poll survey said they never ...
Cambridge, USA-based Vesalius Therapeutics has entered into a multi-target strategic alliance with the UK’s GSK to discover ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback